167 related articles for article (PubMed ID: 25019640)
1. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.
Seiwert TY; Wang X; Heitmann J; Villegas-Bergazzi V; Sprott K; Finn S; O'Regan E; Farrow AD; Weichselbaum RR; Lingen MW; Cohen EE; Stenson K; Weaver DT; Vokes EE
PLoS One; 2014; 9(7):e102112. PubMed ID: 25019640
[TBL] [Abstract][Full Text] [Related]
2. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract][Full Text] [Related]
3. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
Vaezi A; Wang X; Buch S; Gooding W; Wang L; Seethala RR; Weaver DT; D'Andrea AD; Argiris A; Romkes M; Niedernhofer LJ; Grandis JR
Clin Cancer Res; 2011 Aug; 17(16):5513-22. PubMed ID: 21737503
[TBL] [Abstract][Full Text] [Related]
4. Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo.
Köberle B; Ditz C; Kausch I; Wollenberg B; Ferris RL; Albers AE
Int J Oncol; 2010 May; 36(5):1277-84. PubMed ID: 20372803
[TBL] [Abstract][Full Text] [Related]
5. ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.
Prochnow S; Wilczak W; Bosch V; Clauditz TS; Muenscher A
Clin Oral Investig; 2019 Aug; 23(8):3319-3329. PubMed ID: 30498981
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Ameri A; Mortazavi N; Khoshbakht Ahmadi H; Novin K
Asian Pac J Cancer Prev; 2016; 17(S3):87-91. PubMed ID: 27165214
[TBL] [Abstract][Full Text] [Related]
8. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Mullane SA; Werner L; Guancial EA; Lis RT; Stack EC; Loda M; Kantoff PW; Choueiri TK; Rosenberg J; Bellmunt J
Clin Genitourin Cancer; 2016 Aug; 14(4):352-9. PubMed ID: 26778300
[TBL] [Abstract][Full Text] [Related]
9. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.
Chiu TJ; Chen CH; Chien CY; Li SH; Tsai HT; Chen YJ
J Transl Med; 2011 Mar; 9():31. PubMed ID: 21426588
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
11. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.
Bhagwat NR; Roginskaya VY; Acquafondata MB; Dhir R; Wood RD; Niedernhofer LJ
Cancer Res; 2009 Sep; 69(17):6831-8. PubMed ID: 19723666
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
13. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
Ko EC; Genden EM; Misiukiewicz K; Som PM; Kostakoglu L; Chen CT; Packer S; Kao J
Oncol Rep; 2012 Feb; 27(2):467-74. PubMed ID: 22020564
[TBL] [Abstract][Full Text] [Related]
14. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
15. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Huang PY; Li Y; Mai HQ; Luo RZ; Cai YC; Zhang L
Oral Oncol; 2012 Oct; 48(10):964-968. PubMed ID: 22571922
[TBL] [Abstract][Full Text] [Related]
16. Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
Kirschner K; Melton DW
Anticancer Res; 2010 Sep; 30(9):3223-32. PubMed ID: 20944091
[TBL] [Abstract][Full Text] [Related]
17. Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies.
Stein AP; Swick AD; Smith MA; Blitzer GC; Yang RZ; Saha S; Harari PM; Lambert PF; Liu CZ; Kimple RJ
Cancer Med; 2015 May; 4(5):699-712. PubMed ID: 25619980
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
Deloia JA; Bhagwat NR; Darcy KM; Strange M; Tian C; Nuttall K; Krivak TC; Niedernhofer LJ
Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
[TBL] [Abstract][Full Text] [Related]
19. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]